Platinum based chemoradiotherapy is the standard of care for inoperable non-small cell lung cancer (NSCLC). With evidence that NSCLC can have a dose dependent response with stereotactic ablative radiotherapy (SABR), we hypothesize that a SABR boost on residual tumor treated with chemoradiotherapy could increase treatment efficacy. The purpose of this study was to determine feasibility of such an approach.
from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2Exm3Xj
Δευτέρα 9 Απριλίου 2018
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
An examination of the etiologic overlap between the genetic and environmental influences on insomnia and common psychopathology. Depre...
-
is the premiere name in online OSHA Outreach training and safety courses. Our interactive courses include 10 hour and 30 hour OSHA Outreach,...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Masters Thesis Proposal Outline INTRODUCTION (1 PAGE) • What is the general topic area • Why this topic is relevant/important (how important...
-
Publication date: Available online 5 April 2017 Source: European Annals of Otorhinolaryngology, Head and Neck Diseases Author(s): C.A. Ri...
-
Abstract Background The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive ...
-
6 Top Reference Sites to Write a Winning Research Paper . Tina 6 Top Reference Sites to Write a Winning Research Paper. There may be guideli...
-
Abstract An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 se...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου